H1 vs IQVIA: Which HCP Data Platform Fits Your Pharma Commercial Team in 2026

H1 vs IQVIA: the short answer

H1 vs IQVIA is less a head-to-head than a choice between two different jobs. H1 is an HCP intelligence platform: it profiles doctors and experts using publications, clinical trials, congress activity, payments and claims, which makes it strong for KOL identification, medical affairs, trial site work and specialist targeting. IQVIA, through OneKey, Xponent and its wider commercial data, is the reference data and prescription backbone that many field forces, territory alignments and incentive plans run on. Pharma commercial teams targeting HCPs often need IQVIA-style reference and prescription data underneath, and may add H1 when expertise and influence matter as much as volume.

So the real question is which problem you are solving. If you need a clean master list of every prescriber and account, tied to prescription data that sales crediting can use, IQVIA is the established default. If you need to find and understand the 300 specialists who shape treatment in a rare or specialty indication, H1 is built for that.

This guide sets out each vendor's published figures, explains what each is designed for, gives a scorecard and a match test you can run before signing, works through a specialty launch example, and covers when you need both or neither. It is written for commercial operations, brand, medical affairs and data leaders at pharma and biotech companies.

Why H1 and IQVIA are not like-for-like

Most comparison lists put H1 and IQVIA in the same row of a table. They overlap at the edges, but their centres of gravity are different.

IQVIA sells several layers that commercial teams use together. OneKey is reference data: the records for HCPs and healthcare organisations, their addresses, specialties and affiliations, maintained by data operators and change requests. Xponent and related products are prescription data used for targeting, sizing and sales crediting. IQVIA then sells analytics, technology and field services on top. IntuitionLabs' February 2026 review of HCP data providers notes IQVIA's prescription and dispensing datasets cover roughly 90 to 93 percent of US retail pharmacy claims.

H1 started from the expertise side. Its HCP Universe product combines public, proprietary and contributory sources into profiles that show what each HCP publishes, which trials they run, which congresses they attend, what industry payments they receive and what their claims activity looks like. H1 sells this to medical, clinical and commercial teams, with Prescriber Universe aimed at commercial targeting and Commercial Intelligence Streams delivering the data into a company's own platforms. It has also moved into provider data management: it acquired Veda Data Solutions in June 2025 (Fierce Healthcare) and Defacto Health on 11 September 2026 (HLTH), building on its earlier acquisition of Ribbon Health.

The practical consequence: IQVIA answers "who are all the prescribers, where do they work and what do they write", while H1 answers "who are the experts and influencers in this disease, and what are they doing". Both claim the other's ground to a degree, which is why a test on your own data matters.

H1 vs IQVIA OneKey by the numbers

The figures below are each vendor's own, or a named third party's, read in November 2026. They are not measured the same way, so treat them as orientation, not a ranking.

How to read this. H1's 12 million profiles are global and expertise-led; OneKey's 11.3 million are a US reference count. The numbers are close but the records serve different purposes. Alpha Sophia's June 2026 comparison sums up the trade-off on IQVIA's side: its global scale and rigour are hard to match, but smaller specialty teams targeting a few states may find OneKey heavier and costlier than they need.

Which fits your team: use cases side by side

Field targeting

You need every prescriber and account, clean addresses, sample eligibility, and prescription data that drives call plans and sales crediting. IQVIA's OneKey plus Xponent is designed for exactly this, and is what most territory and incentive compensation processes are built around.

KOL and specialist

You need to find the few hundred physicians who publish, run trials, speak at congresses and refer patients in one indication. H1's profiles and search are built around that expertise and influence data.

Medical affairs

Publications, trials, congress activity and payments matter more than prescription volume. H1 sells dedicated medical solutions, HCP Universe, Medical Intelligence Streams and Medical MDM, alongside its commercial ones.

Data backbone

You need identifiers that every system keys off, change requests, and hierarchies for account-based selling. OneKey is the long-established option, alongside Veeva OpenData. H1 offers Commercial MDM and data streams, so ask how its identifiers map to the ones your CRM already uses.

The scorecard: eight things to test before you sign

• Coverage of your target list

  Send both vendors the same de-identified list of target HCPs with NPIs and count exact matches, probable matches and misses, split by specialty and state.

  • Same list for both
  • Include your hardest-to-find experts

• Accuracy on known HCPs

  Have field or MSL staff check 50 profiles they know well for address, affiliation, specialty and current activity.

  • Field knowledge beats brochures

• Expertise signal in your indication

  Ask each vendor to produce its top 50 experts for your disease area and compare with your medical team's own list.

  • Look at who is missing
  • Ask how influence is scored

• Claims and prescription data rights

  Ask what the claims or prescription data in each product may be used for: targeting only, or also sales crediting and incentive compensation.

  • Get permitted uses in writing

• Delivery into your stack

  Confirm format, frequency and whether incremental changes are flagged for your CRM, MDM and warehouse, and ask for a sample file.

  • Ask for the schema
  • Test a delta load

• Identifier mapping

  Check how each vendor's HCP and HCO IDs map to NPI and to the IDs your CRM and data warehouse already use.

  • Count crosswalks needed
  • Ask who maintains them

• Change requests and refresh

  Raise real corrections during the trial and time them. Ask how often profiles, affiliations and claims refresh.

  • Measure, do not assume

• Total cost over the term

  Neither vendor publishes prices. Compare licence, seats, extra markets, integration build and any switching or remapping work over the full term.

  • Price integration separately

How to run a fair H1 vs IQVIA test

A worked example: a specialty launch with a small team

Consider a biotech preparing to launch a therapy for a rare autoimmune condition in the US. It plans 25 field reps and 8 MSLs, runs Veeva Vault CRM, and its forecast suggests that a few thousand specialists treat most of the patients, with a few hundred academic physicians shaping how the disease is treated.

What it needs. A clean master of every relevant rheumatologist, dermatologist and treating centre, with addresses, affiliations and sample eligibility, for CRM and territory design. A view of who treats the condition, using claims. And a ranked list of the experts who publish, run trials and speak, for MSL planning and advisory boards.

How the two map on. Reference data for CRM is the classic OneKey job, though since the 18 August 2025 IQVIA and Veeva agreement the company could equally pick Veeva OpenData and still use IQVIA data where needed; our Veeva OpenData vs IQVIA OneKey guide covers that choice. The expert list is H1's core strength. The treater view could come from either side, or from a claims specialist, which our Komodo Health vs IQVIA comparison covers.

A sensible sequence. Medical affairs licenses an expertise platform such as H1 when MSL planning starts, well before launch. Commercial chooses reference data alongside the CRM build and licenses prescription data once the brand needs targeting and crediting. One HCP master, keyed on NPI, links all three, so the MSL's expert list, the rep's call plan and the brand's dashboards describe the same physicians.

What it should not do. Buy a broad national prescription audit for 25 reps before it knows which specialties drive volume, or let each team pick a vendor without a shared identifier strategy. The second mistake is the expensive one: three systems with three IDs for the same doctor means months of reconciliation later. Our guide to HCP segmentation in pharma shows how the combined data feeds targeting once it is joined.

Common mistakes when comparing H1 and IQVIA

• Comparing headline profile counts

  Global expertise profiles and US reference records are counted differently. Only a match test on your list tells you anything.

• Buying for one team in isolation

  Medical buys one platform, commercial another, and nobody owns the HCP identifiers that connect them.

• Assuming claims data allows crediting

  Data licensed for targeting and insight may not be licensed for sales crediting or incentive compensation. Ask first.

• Skipping the compliance review

  Using medical-side expertise data for promotional targeting needs your compliance team's sign-off on how it is used and by whom.

• Ignoring integration cost

  A platform the field opens in a browser is different from data that must flow into CRM and the warehouse. Price the build.

• Locking in too early

  For a first launch, keep terms short until you know which specialties and accounts actually drive the brand.

When you need both, one, or neither

You likely need both if you are a mid-sized or large company with a field force on national targeting and a medical affairs team working with experts in specialty indications. IQVIA-style reference and prescription data runs the commercial engine; H1 adds the expertise layer. The work is in joining them through an MDM layer with clear survivorship rules, which our article on survivorship and the golden record explains.

IQVIA alone usually suits primary care or broad specialty brands where prescription volume drives targeting and the incentive plan already depends on IQVIA data.

H1 alone can suit a pre-commercial or early-commercial biotech whose first need is understanding the expert landscape and trial sites, with reference data added at the CRM build.

Neither yet if you have no field team and a small, well-known universe of specialists that public NPI and Open Payments data plus your own research can cover. Revisit when you plan a launch.

How Greenwolf helps

We do not resell H1, IQVIA or any other data vendor, and we are not paid by them, so our interest is only that the data fits your systems and your decisions. Our founder came up through pharma commercial operations consulting at ZS, and most of our work is joining reference, prescription, claims, specialty pharmacy and CRM data into one layer that brand, sales and medical teams can all use.

On a vendor decision we design and run the match test, score the results, map the integration into your CRM, MDM and warehouse, and price the full term honestly. After a decision we build the crosswalks, feeds and dashboards and support the team that owns them. For a specialty therapy provider whose identifiers did not line up across sources, building clean identifiers and an MDM structure with automated pipelines cut manual reporting work by 60 to 80 percent. See our pharma commercial analytics services for the full scope, and MDM implementation services for the identifier work.

Questions about H1 and IQVIA